Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI
Bikash Panthi, Beatriz E. Adrada, Rosalind P. Candelaria, Mary S. Guirguis, Clinton Yam, Medine Böge, Huiqin Chen, Kelly K. Hunt, Lei Huo, Ken‐Pin Hwang, Anil Korkut, Deanna L. Lane, H. Carisa Le-Petross, Jessica W. T. Leung, Jennifer K. Litton, Rania M. Mohamed, Benjamin C. Musall, Sanaz Pashapoor, Miral Patel, Frances Perez, Jong Bum Son, Alastair M. Thompson, Vicente Valero, Peng Wei, Jason B. White, Zhan Xu, L. Pinsky, Debu Tripathy, Wei Yang, Jingfei Ma, Gaiane M. Rauch
Abstract
Early assessment of neoadjuvant systemic therapy (NAST) response for triple-negative breast cancer (TNBC) is critical for patient care in order to avoid the unnecessary toxicity of an ineffective treatment. We assessed functional tumor volumes (FTVs) from dynamic contrast-enhanced (DCE) MRI after 2 cycles (C2) and 4 cycles (C4) of NAST as predictors of response in TNBC. A group of 100 patients with stage I-III TNBC who underwent DCE MRI at baseline, C2, and C4 were included in this study. Tumors were segmented on DCE images of 1 min and 2.5 min post-injection. FTVs were measured using the optimized percentage enhancement (PE) and signal enhancement ratio (SER) thresholds. The Mann–Whitney test was used to compare the performance of the FTVs at C2 and C4. Of the 100 patients, 49 (49%) had a pathologic complete response (pCR) and 51 (51%) had a non-pCR. The maximum area under the receiving operating characteristic curve (AUC) for predicting the treatment response was 0.84 (p < 0.001) for FTV at C4 followed by FTV at C2 (AUC = 0.82, p < 0.001). The FTV measured at baseline was not able to discriminate pCR from non-pCR. FTVs measured on DCE MRI at C2, as well as at C4, of NAST can potentially predict pCR and non-pCR in TNBC patients.